<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273883</url>
  </required_header>
  <id_info>
    <org_study_id>09-008292</org_study_id>
    <nct_id>NCT01273883</nct_id>
  </id_info>
  <brief_title>A Trial of Magnesium Dependent Tinnitus</brief_title>
  <official_title>A Phase III Trial of Magnesium Dependent Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to examine any potential benefit in lessening the severity of
      tinnitus (ringing or booming sensation in one or both ears) in subjects supplemented with
      magnesium (532 mg daily).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Descriptions of tinnitus date back to the time of ancient Egypt, yet science has failed to
      unravel the mysterious underlying mechanisms that produce these subjective auditory
      perceptions of sound. These perceptions may be manifestations of damage resulting from noise
      exposure, ototoxicity, or other abnormal conditions of the auditory system. However, many
      individuals have idiopathic tinnitus for which no specific cause can be determined. Although
      often presenting in conjunction with hearing loss, the magnitude of hearing loss does not
      necessarily correspond with the severity of tinnitus. In addition, some individuals reporting
      tinnitus experience concomitant hyperacusis. This relationship suggests these processes may
      be linked by underlying imbalances at the level of the hair cell. The possible influence of
      magnesium (Mg) and its antagonist, calcium, has been discussed in the literature as a
      contributing factor in the mitigation of noise-induced hearing loss, ototoxicity, and the
      hyperexcitability of the auditory system. Permanent and temporary changes in auditory
      function have been linked to nutritional deficiencies of magnesium. Mg deficiency has
      resulted in increased susceptibility to noise-induced hearing loss, ototoxicity, and
      hyperexcitability of the auditory system.

      The recommended daily allowance (RDA) for Mg in adults is 4.5 mg/kg; however, all age groups
      of Americans fall short of the RDA for Mg by 100 mg daily. This lack of appropriate magnesium
      intake may have negative consequences. For example, the putative Mg mechanism within the
      auditory system involves a metabolic cellular cascade of events. Specifically, Mg deficiency
      leads to increased permeability of the calcium channel in the hair cells with a consequent
      over-influx of calcium, an increased release of glutamate via exocytosis, and overstimulation
      of N-methyl-D-aspartate receptors on the auditory nerve fibers. Recent studies of both
      noise-induced hearing loss and idiopathic sensorineural hearing loss have suggested that Mg
      supplementation may lessen the severity of tinnitus in patients. Mg improved hearing recovery
      and lessened tinnitus in patients with idiopathic sudden hearing loss. More recently, a
      well-controlled study that Mg was a relatively safe and convenient adjunct to corticosteroid
      treatment for enhancing the improvements of hearing in acute-onset sensorineural hearing loss
      at a dose of 4 g. The protective effect of Mg in noise-induced hearing loss has been
      previously reported.

      Despite these encouraging findings, no controlled study has examined the effect of Mg
      supplementation for subjects with moderate to severe tinnitus.

      In this study subjects made 4 visits to the clinic over about 2 months. At the first visit,
      subjects had a hearing test. Prior to beginning each round of supplements, subjects were
      asked to rate the severity of their tinnitus on a 1-10 scale, and to complete the Tinnitus
      Handicap Inventory (THI) questionnaire. Subjects were then randomized to 1 of 2 groups. One
      group began with 532 mg of Mg for 25 days, the other group began with a placebo supplement
      for 25 days.

      At visit 2, the subjects had a hearing test, rated their tinnitus, and completed the THI
      questionnaire as well as the Treatment Period Survey. Subjects did not take any supplement
      for 2 weeks, then returned for visit 3.

      At Visit 3, the subjects had a hearing test, rated their tinnitus, and completed the THI
      questionnaire they then took the opposite supplement (placebo or Mg) for 25 days.

      At Visit 4, the subjects had a hearing test, rated their tinnitus, and completed the THI
      questionnaire as well as the Treatment Period Survey.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tinnitus Distress Rating</measure>
    <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
    <description>This is a single-item patient-reported distress rating on a 0-10 scale, with 0=no tinnitus to 10=worst possible tinnitus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Subjects</measure>
    <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
    <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Men</measure>
    <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
    <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Women</measure>
    <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
    <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Magnesium first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then magnesium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium</intervention_name>
    <description>Magnesium 532 mg a day</description>
    <arm_group_label>Magnesium first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching form/dosage</description>
    <arm_group_label>Magnesium first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then magnesium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Normal Kidney function (last checked within 6 months). Serum creatinine levels 1.5
             mg/dL or below for females, 2.0 mg/dL for males.

          -  An audiogram within the past 6 months

          -  Mayo Clinic patients who live in Phoenix area

        Exclusion criteria:

          -  Any participant with decreased kidney function within past 6 months, over 1.5 mg/dL
             for females and over 2.0 mg/dL for males.

          -  Current treatment with Lithium

          -  Tinnitus rating with 0, 1, or 2 on the 0-10 Tinnitus scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Cevette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cevette MJ, Barrs DM, Patel A, Conroy KP, Sydlowski S, Noble BN, Nelson GA, Stepanek J. Phase 2 study examining magnesium-dependent tinnitus. Int Tinnitus J. 2011;16(2):168-73.</citation>
    <PMID>22249877</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <results_first_submitted>January 7, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Cevette</investigator_full_name>
    <investigator_title>Associate Professor of Audiology, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>hearing</keyword>
  <keyword>magnesium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Magnesium First, Then Placebo</title>
          <description>Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Magnesium</title>
          <description>Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Received at least 1 dose of study drug.</participants>
                <participants group_id="P2" count="19">Received at least 1 dose of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 2 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive magnesium first and placebo first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.45" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tinnitus Distress Rating</title>
        <description>This is a single-item patient-reported distress rating on a 0-10 scale, with 0=no tinnitus to 10=worst possible tinnitus.</description>
        <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
        <population>Not all subjects completed the distress rating scale.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium</title>
            <description>Magnesium 532 mg administered daily in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered daily in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Tinnitus Distress Rating</title>
          <description>This is a single-item patient-reported distress rating on a 0-10 scale, with 0=no tinnitus to 10=worst possible tinnitus.</description>
          <population>Not all subjects completed the distress rating scale.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="1.94"/>
                    <measurement group_id="O2" value="5.82" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="2.30"/>
                    <measurement group_id="O2" value="5.46" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Subjects</title>
        <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
        <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
        <population>Not all subjects completed the THI questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium</title>
            <description>Magnesium 532 mg administered daily in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered daily in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Subjects</title>
          <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
          <population>Not all subjects completed the THI questionnaire.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="22.2"/>
                    <measurement group_id="O2" value="25.7" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="19.9"/>
                    <measurement group_id="O2" value="23.2" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Men</title>
        <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
        <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
        <population>Not all male subjects completed the THI questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium</title>
            <description>Magnesium 532 mg administered daily in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered daily in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Men</title>
          <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
          <population>Not all male subjects completed the THI questionnaire.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="24.7"/>
                    <measurement group_id="O2" value="27.2" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="21.5"/>
                    <measurement group_id="O2" value="25.3" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Women</title>
        <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
        <time_frame>Pre-treatment, Post-treatment, up to four weeks</time_frame>
        <population>Not all the female subjects completed the THI questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium</title>
            <description>Magnesium 532 mg administered daily in either first intervention period or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered daily in either first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Average Tinnitus Handicap Inventory (THI) Across All Women</title>
          <description>The Tinnitus Handicap Inventory measures the extent that tinnitus interferes with daily activities and sleep.The questionnaire consists of 25 questions, the score can range from 0 (slight problem) to 100 (catastrophic). The score can be converted to a categorical variable as follows: 0-16=Slight; 18-36=Mild; 38-56=Moderate; 58-76=Severe; 78-100=Catastrophic.</description>
          <population>Not all the female subjects completed the THI questionnaire.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="14.7"/>
                    <measurement group_id="O2" value="22.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="14.4"/>
                    <measurement group_id="O2" value="18.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Tinnitus patients who presented to the Ear, Nose, and Throat (ENT) department of the Mayo Clinic in Arizona from 2009 to 2012 were screened and asked to participate.</time_frame>
      <desc>Adverse events during the study will be reported to the study team by the research coordinator who will query the subjects as part of each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Magnesium</title>
          <description>Magnesium 532 mg administered daily in either first intervention period or second intervention period.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered daily in either first intervention period or second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Intermittent Ankle Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lower Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Emergency Room Visit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael J. Cevette</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-301-7020</phone>
      <email>mcevette@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

